Cipla is expected to see a decent June quarter with revenues estimated to increase in upper single digits on a year on year basis and net profits seeing a mid single digit growth
Cipla's share price declined by 0.56 per cent, ending the day's trade at Rs 1,507.50 apiece on the BSE
The partnership between Orchid Pharma and Cipla combines Orchid's innovative drug development capabilities with Cipla's extensive distribution network and market presence